Compare TILE & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | HRMY |
|---|---|---|
| Founded | 1973 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1994 | 2020 |
| Metric | TILE | HRMY |
|---|---|---|
| Price | $33.08 | $35.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $36.00 | ★ $44.11 |
| AVG Volume (30 Days) | 501.3K | ★ 910.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 32.43 | 7.97 |
| EPS | 0.40 | ★ 0.55 |
| Revenue | ★ $1,386,854,000.00 | $868,453,000.00 |
| Revenue This Year | $6.72 | $19.75 |
| Revenue Next Year | $5.61 | $12.88 |
| P/E Ratio | $81.63 | ★ $65.09 |
| Revenue Growth | 5.41 | ★ 21.51 |
| 52 Week Low | $20.37 | $25.52 |
| 52 Week High | $36.66 | $40.87 |
| Indicator | TILE | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 51.31 |
| Support Level | $27.15 | $35.05 |
| Resistance Level | $34.97 | $35.47 |
| Average True Range (ATR) | 1.14 | 1.59 |
| MACD | -0.25 | -0.20 |
| Stochastic Oscillator | 48.33 | 46.08 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.